Main info

Identifier:

HO162 AML

Sponsor:

HOVON

Working group party:

Leukemia

Stage:

1st Line

Echelon:

Level A

Included patients:

0

(of 25)

Active sites:

0

(of 4)

4 sites are pending

Title:

A phase II multicenter study to assess the feasibility and efficacy of the addition of an interphase cycle with flotetuzumab prior to start conditioning for an allogeneic HCT in AML with detectable MRD after 2 cycles of intensive chemotherapy

Timeline

News

Details

Phase:

Prospective Phase II study

Monitoring Type:

Site Evaluation Visit

Objectives:

Registration Details

Participating Sites

= Active hospitals

= Inactive hospitals